Oral Session 1-5A AML: AlloHSCT

[OS1-5A-4] Evaluation of TIM-3+ AML stem cells should be significant to predict early relapses after allo-SCT

Hidetoshi Irifune^1,2, Teppei Sakoda^1,2, Yoshikane Kikushige², Goichi Yoshimoto², Toshihiro Miyamoto^2,3, Koichi Akashi^1,2,3 (1.Center for Cellular & Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan, 2.Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 3.Department of Hematology, Oncology & Cardiovascular, Kyushu University Hospital, Fukuoka, Japan)